EsoCap AG and tesa Labtec GmbH announced that they have entered into a cooperation on the industrial development of a unique drug delivery technology for diseases of the upper astrointestinal tract. This collaboration leverages the collective expertise of a strong partner in the thin film technology with an innovative biopharmaceutical company.
“This cooperation agreement allows EsoCap to work with a proven industrial partner on the next steps of development of EsoCap’s drug delivery technology in the upper gastrointestinal tract” said Dr. Werner Tschollar, Chairman of the Board of EsoCap. “We are committed to working closely with tesa Labtec to rapidly enter clinical trials to develop therapies for patients suffering of diseases of the upper gastrointestinal tract. The EsoCap technology may be beneficial in at least 6 indications affecting 370 Mio pa-tients.”
Under the terms of this agreement, tesa Labtec is working on the implementation of their thin film know-how applied to the EsoCap unique drug delivery technology for diseases of the upper gastrointestinal tract.
“As a company committed to delivering pharmaceutical solutions based on our thin film technology” said Dr. Ingo Lehrke, General Manager of tesa Labtec “we are highly interested in expanding the field of applications of our technology. We look forward to the opportunity to work with a company like EsoCap which brings a tremendous innovation in the area of drug delivery in the upper gastrointestinal tract.”